Objective To investigate the clinical effect and safety of linagliptin combined with insulin aspart 50 in the treatment of hepatogenous diabetes (HD) .Methods A total of 57 patients with HD who visited The People's Hospital of Liaoning Province from October 2014 to February 2016 were enrolled and randomly divided into insulin aspart 50 group (group A, 28 patients) and linagliptin combined with insulin aspart 50 group (group B, 29 patients) .The two groups were compared in terms of blood glucose, insulin, C-peptide, glucose disposition index (DI) , glycosylated hemoglobin A1c (Hb A1c) , glucagon, and daily insulin dose at baseline and after 12 weeks of treatment.The adverse events including hypoglycemia were observed.The paired t-test was used for comparison of continuous data within one group, and the independent-samples t test was used for comparison of continuous data between groups;the chi-square test was used for comparison of categorical data between groups.Results After 12 weeks of treatment, both groups had significant reductions in blood glucose at four time points (t=5.357-21.380, all P<0.05) and significant increases in the insulin level at 30, 60, and 120 minutes (t=2.222-6.491, all P<0.05) .Compared with group A, group B had significantly lower levels of Hb A1 c and glucagon, daily insulin dose, and blood glucose and insulin levels at 30, 60, and 120 minutes (t=3.136-15.096, all P<0.05) , as well as significantly higher DI and levels of C-peptide at four time points (t=2.994-10.813, all P<0.05) .Group A had a significantly higher incidence rate of hypoglycemia than group B (28.6% vs 3.4%, χ2=5.005, P<0.05) .Conclusion Linagliptin combined with insulin aspart 50 can effectively control blood glucose in patients with HD and has good safety.